EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy

Lara Šošić, Marta Paolucci iD, Alessandro Streuli iD, David A Melillo, Tianchi Jiang, Raffaela Campana, Claudia C V Lang iD, Thomas M Kündig, Christian Steuer iD, Klaus Eyer iD, Pål Johansen iD

Clinical & Experimental Allergy · 2026-08 · 56 (8) · 881-892

DOI: 10.1111/cea.70276 ↗

At a glance

Journal article in Clinical & Experimental Allergy, published online on 2026-03-10. Written by Lara Šošić and 10 co-authors. Institution: Department of Dermatology, University of Zurich, Schlieren, Switzerland. Major MEDLINE topics: Immunoglobulin G, Desensitization, Immunologic, Epitope Mapping, Antigens, Plant. Cited 1 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Innosuisse - Schweizerische Agentur für Innovationsförderung, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Foundation for Research in Science and the Humanities at the University of Zurich.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Allergen immunotherapy (AIT) is the only curative treatment for allergic diseases, primarily by inducing allergen‐neutralising IgG antibodies. However, its use is limited by frequent allergic adverse events.

Objective

To facilitate the design of IgG‐epitope‐based peptide vaccines, this study aimed to identify IgG‐binding regions on the major birch pollen allergen, Bet v 1 , using patient‐derived immune profiles.

Methods

Blood samples were collected from 30 birch pollen‐allergic patients, both AIT‐treated and untreated; healthy individuals were included as controls. Sera were analysed for allergen‐specific IgE, IgG, and IgG4, and basophil degranulation inhibition was assessed in humanised RBL cells and blood from allergic individuals. We used DropMap microfluidics for single‐cell affinity profiling of IgG‐ and IgG4‐secreting B cells. IgG epitopes were mapped using overlapping peptides and CLIPS technology. Candidate AIT peptides were synthesised on solid phase via Fmoc strategy, and their allergenicity was assessed in basophil degranulation and cellular antigen stimulation assays.

Results

Sera from AIT‐treated patients exhibited elevated IgG and IgG4 levels and enhanced inhibition of basophil degranulation. Single‐cell analysis indicated IgG‐affinity maturation with AIT. IgG‐epitope mapping identified four distinct, non‐overlapping IgG‐binding regions on Bet v 1 . Six peptides derived from these regions were successfully produced and did not induce basophil degranulation in vitro. The application of DropMap microfluidics allowed high‐resolution single B‐cell analysis, providing novel insights into allergen‐specific B‐cell responses and the effects of AIT at the clonal level.

Conclusion

This integrated approach identifies hypoallergenic peptides that selectively engage protective IgG responses and offers a framework for developing safer, next‐generation immunotherapies for allergic disease.

Subjects

MeSH terms (MEDLINE)

Immunoglobulin GDesensitization, ImmunologicEpitope MappingAntigens, PlantAllergensPeptidesRhinitis, Allergic, SeasonalHumansBasophilsFemaleAdultMaleImmunoglobulin EEpitopes

Author keywords

DropMapallergen immunotherapyantibodiesbasophil activation assayepitope mappingsynthetic peptides

Substances

Immunoglobulin GAntigens, PlantAllergensPeptidesBet v 1 allergen, BetulaImmunoglobulin EEpitopes

Authors and institutions

  • Department of Dermatology, University of Zurich, Schlieren, Switzerland.
  • Laboratory for Functional Immune Repertoire Analysis, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
  • Laboratory for Pharmaceutical Analytics, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
  • Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.

ORCID profiles: Marta Paolucci, Alessandro Streuli, Claudia C V Lang, Christian Steuer, Klaus Eyer, Pål Johansen

Funding

  • Innosuisse - Schweizerische Agentur für Innovationsförderung
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Foundation for Research in Science and the Humanities at the University of Zurich
  • Foundation for Research in Science and the Humanities

Cite

APA

Šošić, L., Paolucci, M., Streuli, A., Melillo, D. A., Jiang, T., Campana, R., Lang, C. C. V., Kündig, T. M., Steuer, C., Eyer, K., & Johansen, P. (2026). Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy. Clinical & Experimental Allergy, 56(8), 881-892. https://doi.org/10.1111/cea.70276

Vancouver

Šošić L, Paolucci M, Streuli A, Melillo DA, Jiang T, Campana R, et al. Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy. Clinical & Experimental Allergy. 2026;56(8):881-892. doi:10.1111/cea.70276

BibTeX
@article{oi2026,
  author = {Šošić, Lara and Paolucci, Marta and Streuli, Alessandro and Melillo, David A and Jiang, Tianchi and Campana, Raffaela and Lang, Claudia C V and Kündig, Thomas M and Steuer, Christian and Eyer, Klaus and Johansen, Pål},
  title = {Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy},
  journal = {Clinical & Experimental Allergy},
  year = {2026},
  volume = {56},
  number = {8},
  pages = {881--892},
  doi = {10.1111/cea.70276}
}
Start for free →